Other therapeutic regimens combining pegylated IFN-α-2α and dacarbazine [116], pegylated IFN-α-2β and temozolamide [117], and IFN-α-2β and tremelimumab [118] have been proven to be effective in advanced melanoma patients, with acceptable toxicity and promising durable antitumor activity. The gene discussed is IFNA2; the disease is melanoma.